Widespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Nathan M. Denlinger, DO
Articles by Nathan M. Denlinger, DO